Exagen Inc

Exagen Inc. designs, develops, and commercializes testing products under the AVISE brand in the United States. These products help healthcare providers diagnose, prognose, and monitor complex rheumatic and autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's portfolio includes AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE Anti-Histone, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE SLE Monitor, AVISE MTX, and AVISE HCQ. Exagen has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. Formerly known as Exagen Diagnostics, Inc., it changed its name to Exagen Inc. in January 2019. The company was incorporated in 2002 and is headquartered in Vista, California.